Acquired platelet antagonism: off-target antiplatelet effects of malignancy treatment with tyrosine kinase inhibitors.

摘要: Platelets can contribute to tumor progression and metastasis. Cancer patients are at increased risk of thrombosis, advanced stages cancer associated with thrombocytosis or platelet reactivity. Tyrosine kinase inhibitors (TKIs) widely used as a targeted strategy for treatment, the aim prolonging progression-free survival patients. Because their broad target spectrum, most TKIs inevitably have off-target effects. rely on tyrosine activity activation. Frequently observed side effects lowering count inhibition functions, whether not accompanied by an bleeding risk. In this review, we give insights into: (i) 38 that currently treatment different types cancer, either market in clinical trials; (ii) how distinct inhibit activation mechanisms platelets; (iii) consequences antiplatelet TKI treatment. For several TKIs, knowledge affinity targets does align published platelets reported events. This review should raise awareness potential which will be enhanced presence antithrombotic drugs.